Inhibrx Biosciences, Inc — Biomedical Watch V2

Traitements9programmes

Essais3liés

Publications6liées

SourceDBlocale

Traitements

9

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Carboplatin AUC-5This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.	Cancer	Phase 1/2	À vérifier	United States, Singapore, South Korea, Taiwan	À vérifier
Carboplatin AUC-6This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.	Cancer	Phase 1/2	À vérifier	United States, Singapore, South Korea, Taiwan	À vérifier
INBRX-106 - Hexavalent OX40 agonist antibodyThis is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.	Cancer	Phase 1/2	À vérifier	United States, Singapore, South Korea, Taiwan	À vérifier
Pembrolizumab 200 mgThis is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone.	Cancer, Parkinson	Phase 1/2	À vérifier	United States, Singapore, South Korea, Taiwan	À vérifier
Pembrolizumab 400 mgResearchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT.	Cancer, Parkinson	Phase 1/2	À vérifier	United States, Singapore, South Korea, Taiwan	À vérifier
Pemetrexed 500 mg/m2This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.	Cancer	Phase 1/2	À vérifier	United States, Singapore, South Korea, Taiwan	À vérifier
Pembrolizumab 200 mgThis is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone.	Parkinson	Phase 3	À vérifier	United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, France, Germany, Hungary, Ireland, Israel, Japan, Poland, Portugal, Russia, South Korea, Spain, …	À vérifier
Pembrolizumab 200 mgThis is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone.	Parkinson	Phase 3	À vérifier	United States, Australia, Belgium, Bulgaria, Canada, China, Estonia, France, Greece, Hungary, Israel, Italy, Japan, Lithuania, Mexico, Portugal, Romania, Russia, Serbia, South Africa, …	À vérifier
INBRX-106 - Hexavalent OX40 agonist antibodyThis is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.	Cancer	Phase 1/2	À vérifier	United States, Singapore, South Korea, Taiwan	À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
INBRX-106 - Hexavalent OX40 agonist antibody	Cancer	Phase 1/2	NCT04198766	Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)	RECRUITING
Pembrolizumab 200 mg	Parkinson	Phase 3	NCT04624204	Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)	ACTIVE_NOT_RECRUITING
Pembrolizumab 200 mg	Parkinson	Phase 3	NCT03765918	Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)	ACTIVE_NOT_RECRUITING

Publications

6

Molécule	Indication / population	Titre	Journal	Date
Carboplatin AUC-6		Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients.	International journal of clinical oncology
Carboplatin AUC-6		Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial.	International journal of radiation oncology, biology, physics
Carboplatin AUC-6		Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020).	Annals of oncology : official journal of the European Society for Medical Oncology
Pemetrexed 500 mg/m2		Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial.	Investigational new drugs
Pemetrexed 500 mg/m2		A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.	Lung cancer (Amsterdam, Netherlands)
Pemetrexed 500 mg/m2		Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.	JAMA oncology